Sibu 15 is indicated as adjunctive therapy in anti-obesity program for:
- Patients with obesity due to an energy imbalance whose body mass index (BMI) of 30 kg/m2 or more;
- Due to an energy imbalance overweight patients with BMI = 27 kg/m2 or higher and who are risk factors for obesity such as type 2 diabetes or dyslipidaemia.
Note:
Sibu 15 should only patients who did not respond properly to a suitable weight loss diet, or those who have lost weight less than 5 kg within 3 months.


Composition and Method of Presentation
The active ingredient is sibutramine 15 mg.